Journal
AGE AND AGEING
Volume 46, Issue 2, Pages 271-277Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ageing/afw192
Keywords
older people; sarcopenia; quality of life; translation; validation
Categories
Funding
- FNRS (Fonds National de la Recherche Scientifique de Belgique-FRS-FNRS)
- International Osteoporosis Foundation
- Servier for the development and validation of the French version of the SarQoL questionnaire
- MRC [MC_U147585819, G0400491, MC_UP_A620_1015, MC_UU_12011/2, MC_U147585827] Funding Source: UKRI
- Medical Research Council [U1475000001, G0400491, MC_U147585824, MC_U147585827, MC_UP_A620_1015, MC_U147585819, MC_UU_12011/2, MC_UU_12011/1, U1475000002, MC_UP_A620_1014] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0513-10085, NF-SI-0508-10082] Funding Source: researchfish
- Versus Arthritis [19583] Funding Source: researchfish
Ask authors/readers for more resources
Background: the first quality of life questionnaire specific to sarcopenia, the SarQoL (R), has recently been developed and validated in French. To extend the availability and utilisation of this questionnaire, its translation and validation in other languages is necessary. Objective: the purpose of this study was therefore to translate the SarQoL (R) into English and validate the psychometric properties of this new version. Design: cross-sectional. Setting: Hertfordshire, UK. Subjects: in total, 404 participants of the Hertfordshire Cohort Study, UK. Methods: the translation part was articulated in five stages: (i) two initial translations from French to English; (ii) synthesis of the two translations; (iii) backward translations; (iv) expert committee to compare the backward translations with the original questionnaire and (v) pre-test. To validate the English SarQoL (R), we assessed its validity (discriminative power, construct validity), reliability (internal consistency, test-retest reliability) and floor/ceiling effects. Results: the SarQoL (R) questionnaire was translated without any major difficulties. Results indicated a good discriminative power (lower score of quality of life for sarcopenic subjects, P = 0.01), high internal consistency (Cronbach's alpha of 0.88), consistent construct validity (high correlations found with domains related to mobility, usual activities, vitality, physical function and low correlations with domains related to anxiety, self-care, mental health and social problems) and excellent test-retest reliability (intraclass coefficient correlation of 0.95, 95% CI 0.92-0.97). Moreover, no floor/ceiling has been found. Conclusions: a valid SarQoL (R) English questionnaire is now available and can be used with confidence to better assess the disease burden associated with sarcopenia. It could also be used as a treatment outcome indicator in research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available